Hot Topics in Pharmacy Hot Topics in Pharmacy Purchasing: Purchasing: Regulatory Regulatory Requirements, New Requirements, New Drugs, and GS1 Drugs, and GS1 Initiative Initiative Lyle Matthews, Pharm.D, Lyle Matthews, Pharm.D, MAM MAM Director, Pharmacy Director, Pharmacy Services Services
38
Embed
Hot Topics in Pharmacy Purchasing: Regulatory Requirements, New Drugs, and GS1 Initiative Lyle Matthews, Pharm.D, MAM Director, Pharmacy Services Eisenhower.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Hot Topics in Pharmacy Hot Topics in Pharmacy Purchasing:Purchasing:
Regulatory Requirements, Regulatory Requirements, New Drugs, and GS1 New Drugs, and GS1
InitiativeInitiative
Lyle Matthews, Pharm.D, MAMLyle Matthews, Pharm.D, MAM
Eisenhower Medical CenterEisenhower Medical Center
GoalsGoals
Describe the three most Describe the three most challenging regulatory challenging regulatory requirements of regulatory requirements of regulatory agencies and State Boards of agencies and State Boards of Pharmacy involving Pharmacy Pharmacy involving Pharmacy Purchasing Professionals today.Purchasing Professionals today.
Goals (cont.)Goals (cont.)
List the three most interesting new List the three most interesting new medications coming in late 2011 and medications coming in late 2011 and 2012.2012.
Describe what the GS1 or Serial Describe what the GS1 or Serial NDC number initiative is and what it NDC number initiative is and what it means to Pharmacy Purchasing means to Pharmacy Purchasing ProfessionalsProfessionals
DisclaimersDisclaimers
One Director’s Thoughts (Mine)One Director’s Thoughts (Mine)
Each Organization is DifferentEach Organization is Different
GeneralGeneral Ideas And Philosophies Ideas And Philosophies
Goal is to present concepts that Goal is to present concepts that can be related to your individual can be related to your individual health systemshealth systems
RecallsRecallsTrailer TheftTrailer TheftInvoices (3 years on site?)Invoices (3 years on site?)Controlled SubstancesControlled Substances
InvoicesInvoices222 Forms222 FormsCSOSCSOS
Who is Responsible For Helping Who is Responsible For Helping Control Things?Control Things?
Director of Pharmacy?Director of Pharmacy?Operations Manager?Operations Manager?Technician Supervisor?Technician Supervisor?Nursing Staff?Nursing Staff?O.R. and E.D. Staff?O.R. and E.D. Staff?EveryoneEveryone
Sound Familiar?Sound Familiar?
““I don’t know how the vaccines I don’t know how the vaccines are stored, ask the Buyer.”are stored, ask the Buyer.”
““I don’t know what temperature I don’t know what temperature the refrigerators are supposed to the refrigerators are supposed to be kept, ask the Buyer.”be kept, ask the Buyer.”
““I don’t know who has access to I don’t know who has access to the Automated Dispensing the Automated Dispensing Cabinets, ask the Buyer.”Cabinets, ask the Buyer.”
How Do We Control These How Do We Control These ChallengesChallenges
Communicate With The Communicate With The Pharmacy Management TeamPharmacy Management TeamEnsure They Realize Ensure They Realize YouYou Have to Have to Know What is HappeningKnow What is HappeningEnsure You are Included In all Ensure You are Included In all DiscussionsDiscussions
Everyone is responsible for Everyone is responsible for Regulatory ComplianceRegulatory Compliance
Everyone Has Their hands in Our Everyone Has Their hands in Our Meds – Try to control them.Meds – Try to control them.
Communicate and Solve Communicate and Solve Problems Together As a TeamProblems Together As a Team
Joint Commission Survey Joint Commission Survey Aug. 9-12, 2011 Aug. 9-12, 2011
Magnesium SulfateMagnesium SulfateRecallsRecalls– Notification of Nursing/Medical StaffsNotification of Nursing/Medical Staffs
Expired and Recalled Medication Expired and Recalled Medication Storage – SegregationStorage – SegregationAre you a County/State Cache Are you a County/State Cache Site?Site?
New Medications forNew Medications for2011 and 20122011 and 2012
Some have Financial ImpactSome have Financial Impact
Some have Clinical ImpactSome have Clinical Impact
Some will just have Psychological Some will just have Psychological Impact on Us and Make Our Lives Impact on Us and Make Our Lives DifficultDifficult
Leap of faith for patients who are Leap of faith for patients who are used to having INR’s drawnused to having INR’s drawn
Reports of BleedingReports of Bleeding
EffientEffient(prasugrel)(prasugrel)
Oral Antiplatelet Medication for Oral Antiplatelet Medication for patients following angioplastypatients following angioplasty
No proven reversal agentNo proven reversal agent
Cardiac Surgeons are largely Cardiac Surgeons are largely opposed and/or skepticalopposed and/or skeptical
ProvengeProvenge(Sipuleucel-T)(Sipuleucel-T)
For Advanced Prostate CancerFor Advanced Prostate Cancer
FDA Approved April 2010FDA Approved April 2010
Very complicated administrationVery complicated administration
$93,000 for course of Treatment$93,000 for course of Treatment
Controversial – extends life by Controversial – extends life by approximately 4.5 monthsapproximately 4.5 months
All sorts of problems for DendreonAll sorts of problems for Dendreon
XareltoXarelto(rivaroxaban)(rivaroxaban)
DVT prophylaxis in knee and hip DVT prophylaxis in knee and hip replacement patientsreplacement patientsFDA Approved July 1, 2011FDA Approved July 1, 2011Marketed against Lovenox/CoumadinMarketed against Lovenox/CoumadinTaken orally (10mg daily)Taken orally (10mg daily)Applying for indication for A-fib pts.Applying for indication for A-fib pts.Available in Europe since 2008Available in Europe since 2008
Long acting beta-2 adrenergic Long acting beta-2 adrenergic agonist for COPD patientsagonist for COPD patients
75 mcg capsule daily using the 75 mcg capsule daily using the NeohalerNeohaler
Not for asthma patientsNot for asthma patients
Will be available in 1Will be available in 1stst quarter of quarter of 20122012
BrilintaBrilinta(ticagrelor)(ticagrelor)
FDA Approved July 2011FDA Approved July 2011
$7.24 per day (20% more than $7.24 per day (20% more than Plavix (clopidogrel)Plavix (clopidogrel)
Shown superior to Plavix when Shown superior to Plavix when combined with low dose aspirin to combined with low dose aspirin to prevent heart attacks and strokesprevent heart attacks and strokes
clopidogrel generic in May 2012.clopidogrel generic in May 2012.
YervoyYervoy(ipilimumab)(ipilimumab)
Unresectable or Metastatic Unresectable or Metastatic MelanomaMelanoma
Dose is 3mg/kg IV over 90 min. Dose is 3mg/kg IV over 90 min. every 3 weeks x 4 dosesevery 3 weeks x 4 doses
50 mg and 200 mg vials50 mg and 200 mg vials
Extends life avg. of 4 monthsExtends life avg. of 4 months
$120,000 for 4 dose course$120,000 for 4 dose course
VictozaVictoza(liraglutide)(liraglutide)
For Type 2 DiabetesFor Type 2 Diabetes
GLP-1 analog Targeting Pancreatic GLP-1 analog Targeting Pancreatic beta cellsbeta cells
Increases Insulin Secretion and Increases Insulin Secretion and move sugar into cellsmove sugar into cells
Watch for hints of weight loss help Watch for hints of weight loss help
DificidDificid(fidaxomicin)(fidaxomicin)
Already ReleasedAlready ReleasedFor Clostridium dificile associated For Clostridium dificile associated diarrheadiarrheaOne 200mg tablet BID x 10 daysOne 200mg tablet BID x 10 days$140 per tablet$140 per tabletMore expensive that oral VancoMore expensive that oral Vanco–(less that IV Vanco given orally)(less that IV Vanco given orally)
AvastinAvastin(bevacizumab)(bevacizumab)
Not newNot new
Very Expensive and Very PopularVery Expensive and Very Popular
Controversial indication for Breast Controversial indication for Breast CancerCancer
Keep watching – Changes are Keep watching – Changes are ComingComing
Expiring Patents in 2011Expiring Patents in 2011
LipitorLipitor
ZyprexaZyprexa
LevaquinLevaquin
ConcertaConcerta
ProtonixProtonix
Total sales of $10 Billion in 2010Total sales of $10 Billion in 2010
LipitorLipitor(atorvastatin)(atorvastatin)
Patent expired June 2011Patent expired June 2011Ranbaxy Generic Atorvastatin Ranbaxy Generic Atorvastatin available Nov. 2011available Nov. 2011Significant potential cost savings, Significant potential cost savings, but probably further down the but probably further down the roadroadGuess what Pfizer has proposed?Guess what Pfizer has proposed?
GS1 InitiativeGS1 Initiative
GS1 or Serial NDC Number GS1 or Serial NDC Number ProjectProject
Guidance for Securing the Drug Guidance for Securing the Drug Supply Chain – Standardized Supply Chain – Standardized Numerical Identification for Numerical Identification for Prescription Drug PackagesPrescription Drug Packages
Who are GS1?Who are GS1?
““GS1 is a global organization GS1 is a global organization dedicated to the design and dedicated to the design and implementation of global implementation of global standards and solutions to standards and solutions to improve efficiency and visibility in improve efficiency and visibility in supply and demand chains.”supply and demand chains.”
–From GS1 letter to the FDA April, 2009From GS1 letter to the FDA April, 2009
What does it mean to us?What does it mean to us?
Their goal is to standardize NDC Their goal is to standardize NDC standards globallystandards globally
This would potentially enhance This would potentially enhance supply chain tracking and tracingsupply chain tracking and tracing
Could embed product specific Could embed product specific informationinformation
Thank you for having me again.Thank you for having me again.
Best wishes to the NPPA and all Best wishes to the NPPA and all of the Pharmacy Purchasing of the Pharmacy Purchasing